KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesChange in TaxesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionDividends Paid - CommonDividends Paid - CommonExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares IssuedShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gilead Sciences (GILD) Gains from Investment Securities (2016 - 2026)

Gilead Sciences filings provide 17 years of Gains from Investment Securities readings, the most recent being $332.0 million for Q4 2025.

  • On a quarterly basis, Gains from Investment Securities rose 268.89% to $332.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $451.0 million, a 877.59% increase, with the full-year FY2025 number at $451.0 million, up 877.59% from a year prior.
  • Gains from Investment Securities hit $332.0 million in Q4 2025 for Gilead Sciences, up from $106.0 million in the prior quarter.
  • In the past five years, Gains from Investment Securities ranged from a high of $768.0 million in Q4 2022 to a low of -$815.0 million in Q2 2024.
  • Median Gains from Investment Securities over the past 5 years was $91.0 million (2021), compared with a mean of $55.9 million.
  • Biggest five-year swings in Gains from Investment Securities: crashed 320.42% in 2022 and later skyrocketed 44700.0% in 2023.
  • Gilead Sciences' Gains from Investment Securities stood at -$68.0 million in 2021, then soared by 1229.41% to $768.0 million in 2022, then plummeted by 70.83% to $224.0 million in 2023, then tumbled by 59.82% to $90.0 million in 2024, then skyrocketed by 268.89% to $332.0 million in 2025.
  • The last three reported values for Gains from Investment Securities were $332.0 million (Q4 2025), $106.0 million (Q3 2025), and $439.0 million (Q2 2025) per Business Quant data.